Details
| Original language | English |
|---|---|
| Pages (from-to) | 33378-33384 |
| Number of pages | 7 |
| Journal | RSC Advances |
| Volume | 7 |
| Issue number | 53 |
| Publication status | Published - 3 Jul 2017 |
Abstract
The development of nanoscale drug delivery systems, which can mediate efficient tumor targeting together with high cellular internalization, is crucial for glioma treatment. The combination of therapeutic agents in nanoparticles provides synergistic effects and allows further surface modifications with targeting ligands for specific glioma therapy. To achieve this goal, both doxorubicin and curcumin were encapsulated in polyethylene glycolated niosomes (PEGNIO). The surface of co-drug loaded PEGNIO was modified with tumor homing and penetrating peptide (tLyp-1). Physicochemical properties were determined via dynamic light scattering (DLS) and spectral analysis. Moreover, flow cytometry studies were performed to examine the specific cellular uptake of the tLyp-1 targeted niosomal formulation. In vitro cytotoxicity and inhibition of tumor-like spheroids growth were investigated on human glioblastoma (U87) and human mesenchymal stem cells (hMSC) cells. The results clearly indicated that the strategy by co-administration of doxorubicin and curcumin with tLyp-1 functionalized niosomes could significantly improve anti-glioma treatment.
ASJC Scopus subject areas
- Chemistry(all)
- General Chemistry
- Chemical Engineering(all)
- General Chemical Engineering
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: RSC Advances, Vol. 7, No. 53, 03.07.2017, p. 33378-33384.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Tumor homing and penetrating peptide-conjugated niosomes as multi-drug carriers for tumor-targeted drug delivery
AU - Ag Seleci, Didem
AU - Seleci, Muharrem
AU - Stahl, Frank
AU - Scheper, Thomas
N1 - Funding information: The Deutsche Forschungsgemeinschaft (DFG) within the REBIRTH cluster of excellence funded part of this work. Konrad Adenauer Foundation is acknowledged for the financial support to Didem Ag Seleci. We wish to thank André Jochums for his help with flow cytometry analysis. Special thank to Rebecca Jonczyk and Johanna-Gabriela Walter for technical checking of the manuscript. The publication of this paper was funded by the Open Access Fund of the Leibniz Universitat Hannover.
PY - 2017/7/3
Y1 - 2017/7/3
N2 - The development of nanoscale drug delivery systems, which can mediate efficient tumor targeting together with high cellular internalization, is crucial for glioma treatment. The combination of therapeutic agents in nanoparticles provides synergistic effects and allows further surface modifications with targeting ligands for specific glioma therapy. To achieve this goal, both doxorubicin and curcumin were encapsulated in polyethylene glycolated niosomes (PEGNIO). The surface of co-drug loaded PEGNIO was modified with tumor homing and penetrating peptide (tLyp-1). Physicochemical properties were determined via dynamic light scattering (DLS) and spectral analysis. Moreover, flow cytometry studies were performed to examine the specific cellular uptake of the tLyp-1 targeted niosomal formulation. In vitro cytotoxicity and inhibition of tumor-like spheroids growth were investigated on human glioblastoma (U87) and human mesenchymal stem cells (hMSC) cells. The results clearly indicated that the strategy by co-administration of doxorubicin and curcumin with tLyp-1 functionalized niosomes could significantly improve anti-glioma treatment.
AB - The development of nanoscale drug delivery systems, which can mediate efficient tumor targeting together with high cellular internalization, is crucial for glioma treatment. The combination of therapeutic agents in nanoparticles provides synergistic effects and allows further surface modifications with targeting ligands for specific glioma therapy. To achieve this goal, both doxorubicin and curcumin were encapsulated in polyethylene glycolated niosomes (PEGNIO). The surface of co-drug loaded PEGNIO was modified with tumor homing and penetrating peptide (tLyp-1). Physicochemical properties were determined via dynamic light scattering (DLS) and spectral analysis. Moreover, flow cytometry studies were performed to examine the specific cellular uptake of the tLyp-1 targeted niosomal formulation. In vitro cytotoxicity and inhibition of tumor-like spheroids growth were investigated on human glioblastoma (U87) and human mesenchymal stem cells (hMSC) cells. The results clearly indicated that the strategy by co-administration of doxorubicin and curcumin with tLyp-1 functionalized niosomes could significantly improve anti-glioma treatment.
UR - http://www.scopus.com/inward/record.url?scp=85022006924&partnerID=8YFLogxK
U2 - 10.1039/c7ra05071b
DO - 10.1039/c7ra05071b
M3 - Article
AN - SCOPUS:85022006924
VL - 7
SP - 33378
EP - 33384
JO - RSC Advances
JF - RSC Advances
SN - 2046-2069
IS - 53
ER -